Microbial Bioburden on Oral Solid Dosage Forms

Publication
Article
Pharmaceutical TechnologyPharmaceutical Technology-02-02-2002
Volume 26
Issue 2

Low levels of some microorganisms that are present in oral solid dosage forms are unlikely to present a risk to patients. The amount of water activity in these products can help determine when microbiological testing should be conducted.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content